Real-World Effectiveness of My Dose Coach™-Assisted Basal Insulin Titration in People with Type 2 Diabetes in Saudi Arabia and Kuwait

Abstract

Introduction: My Dose Coach (MDC) is a digital smartphone application approved in multiple countries, including Saudi Arabia and Kuwait, to help people with type 2 diabetes (T2D) titrate their basal insulin as per their clinician-guided, individualized diabetes care plan. Methods: A retrospective, observational cohort analysis was conducted on MDC user data collected from 1 January 2021 to 1 June 2023 in Saudi Arabia and Kuwait. Primary outcome was change in fasting blood glucose (FBG). Key secondary outcomes included time to achieve FBG and HbA1c targets, and time to first hypoglycemia event. Outcomes were analyzed by FBG target status and frequency of MDC usage (high: > 3 days per week; moderate: > 1– ≤ 3 days per week; low: ≤ 1 day per week). Results: Among all users (N = 494), mean ± SD FBG decrease was −44.4 ± 72.5 mg/dL. Mean ± SD time to achieve FBG target was 14.8 ± 20.9 days and 12.8 ± 18.8, 29.1 ± 28.0, and 43.5 ± 41.7 days for high-, moderate-, and low-frequency MDC users, respectively. Individualized FBG targets were achieved by 276 (55.9%) users, and high-frequency of MDC use was associated with better target achievement (p < 0.01). Mean ± SD time to achieve HbA1c target was 48.0 ± 40.5 days. Reduction in HbA1c was more in high-frequency MDC users (18.3%) than low-frequency MDC users (6.3%). Mean ± SD time to the first hypoglycemia event was 4.86 ± 4.8 days. Hypoglycemia events were reported in only seven (1.4%) participants and not significantly correlated with MDC use frequency (p = 0.1431). Conclusions: Current findings show that using MDC is associated with improved glycemic control in people with T2D in Saudi Arabia and Kuwait, with greater benefits observed with higher frequency MDC usage.